Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study
Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study
The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH
Inclusion Criteria:
Exclusion Criteria:
Bethesda, Maryland 20892, United States
St Louis, Missouri 63110, United States
Voorhees Township, New Jersey 08043, United States
Durham, North Carolina 27710, United States
Philadelphia, Pennsylvania 19104, United States
Saint Leonard, New South Wales 2065, Australia
Woolloongabba, Queensland 4102, Australia
Woodville South, South Australia 5011, Australia
Parkville, 3050, Australia
Hanover, D-30625, Germany
Homburg/Saar, D-66421, Germany
Ulm, D-89081, Germany
Florence, 50139, Italy
Naples, 5-80131, Italy